Motohiro Esaki
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Year:
2026
Background: Chronic enteropathy associated with SLCO2A1 gene (CEAS) is a rare hereditary disorder characterized by multiple small intestinal ulcers, chronic anemia, and hypoproteinemia. Initially reported by Okabe et al. [J Jpn Soc Gastroenterol. 1968;65:1114–7] in 1968 as chronic nonspecific multiple ulcers of the small intestine, the condition was later identified as a genetic disorder caused by mutations in the SLCO2A1 gene, which encodes a prostaglandin (PG) transporter. Unlike typical autosomal recessive disorders, CEAS predominantly affects females and is frequently present with extraintestinal manifestations such as digital clubbing, pachydermia, and periostosis. Summary: This review provides a comprehensive summary of the epidemiology, pathogenesis, clinical features, diagnostic criteria, and management of CEAS, with an emphasis on newly established diagnostic protocols in Japan. CEAS is characterized by multiple shallow circumferential or oblique ulcers in the small intestine, often resembling NSAID-induced enteropathy. Laboratory findings typically include iron deficiency anemia and hypoproteinemia, while urinary PG metabolite levels are significantly elevated. Genetic testing for SLCO2A1 mutations, particularly the c.940 + 1G>A splice site mutation, confirms the diagnosis. While symptomatic management with enteral nutrition, iron supplementation, blood transfusions, and albumin infusion is the mainstay of therapy, definitive treatments remain unavailable. Endoscopic balloon dilation may be useful in cases of intestinal strictures, but surgical intervention is frequently required. Key Messages: (i) CEAS should be considered in cases of chronic iron deficiency anemia and hypoproteinemia with unexplained small intestinal ulcers. (ii) Genetic testing for SLCO2A1 mutations, combined with assessment of small intestinal morphology, is essential for accurate diagnosis. (iii) Current treatment options are limited to symptomatic management and surgical intervention, highlighting the need for further research to develop effective therapies.
Year:
2025
Background Conflicting reports exist on the correlation of fecal calprotectin (FC), with the endoscopic severity of small bowel lesions of Crohn’s disease (CD). This study aimed to analyze the correlation between FC and small bowel lesions observed by small bowel capsule endoscopy (CE). Methods This prospective multicenter study involved patients aged 16 to < 60 years with CD of ileal or ileocolonic types without a history of intestinal resection. The participants underwent CE, ileocolonoscopy, and FC within a period of 1 month. Patients with active colonic lesions were excluded. Endoscopic remission (ER) was defined as the absence of an ulcer (≥ 5 mm). The primary endpoint was to determine whether FC could be used to define ER of small bowel lesions in patients with CD. The secondary endpoints were the correlation of CE activity and FC. Results The study involved 49 patients. The correlation between FC and Lewis score was positive with r = 0.436 (P = .002). The receiver operating characteristic curve constructed for ER and FC had an area under the curve of 0.828 (95% confidence interval, 0.694-0.962; P < .001). The cutoff FC for ER was calculated to be 175 μg/g. The correlation between FC and Capsule Endoscopy Crohn’s Disease Activity Index was positive with r = 0.542 (P < .001). Conclusions This study revealed a correlation between small bowel CE activity and FC. Under this condition, small bowel ER can be defined as an FC level of < 175 μg/g, and FC was suggested to be a useful biomarker for monitoring small bowel lesions during the application of treat-to-target strategies.
Year:
2025
In recent years, we have seen a considerable increase in the number of patients with inflammatory bowel diseases of unknown etiology, including both Crohn's disease and ulcerative colitis. Inflammatory bowel diseases can cause intestinal lesions throughout the gastrointestinal tract, necessitating gastrointestinal endoscopy for examining all relevant aspects, especially lesion characteristics, for differential diagnosis and histological diagnosis, to select the appropriate treatment options, determine treatment effectiveness, etc. Specific guidelines are necessary to ensure that endoscopy can be performed in a safe and more tailored and efficient manner, especially since gastrointestinal endoscopy, including enteroscopy, is a common procedure worldwide, including in Japan. Within this context, the Japan Gastroenterological Endoscopy Society has formulated the “Guidelines for the Endoscopic Diagnosis and Treatment of Inflammatory Bowel Diseases” to provide detailed guidelines regarding esophagogastroduodenoscopy, enteroscopy, and colonoscopy procedures for definitive diagnosis, as well as determination of treatment effectiveness in clinical cases of inflammatory bowel diseases.
Year:
2025
Objective This study was performed to evaluate whether the use of CAD EYE (Fujifilm, Tokyo, Japan) for colonoscopy improves colonoscopy quality in gastroenterology trainees. Methods The patients in this multicenter randomized controlled trial were divided into Group A (observation using CAD EYE) and Group B (standard observation). Six trainees performed colonoscopies using a back‐to‐back method in pairs with gastroenterology experts. The primary end‐point was the trainees' adenoma detection rate (ADR), and the secondary end‐points were the trainees' adenoma miss rate (AMR) and Assessment of Competency in Endoscopy (ACE) tool scores. Each trainee's learning curve was evaluated using a cumulative sum (CUSUM) control chart. Results We analyzed data for 231 patients (Group A, n = 113; Group B, n = 118). The ADR was not significantly different between the two groups. Group A had a significantly lower AMR (25.6% vs. 38.6%, P = 0.033) and number of missed adenomas per patient (0.5 vs. 0.9, P = 0.004) than Group B. Group A also had significantly higher ACE tool scores for pathology identification (2.26 vs. 2.07, P = 0.030) and interpretation and identification of pathology location (2.18 vs. 2.00, P = 0.038). For the CUSUM learning curve, Group A showed a trend toward a lower number of cases of missed multiple adenomas by the six trainees. Conclusion CAD EYE did not improve ADR but decreased the AMR and improved the ability to accurately locate and identify colorectal adenomas. CAD EYE can be assumed to be beneficial for improving colonoscopy quality in gastroenterology trainees. Trial registration University Hospital Medical Information Network Clinical Trials Registry (UMIN000044031).
Year:
2023
Collaborators (6)
Tadakazu Hisamatsu
-
Fumihito Hirai
-
Hiroshi Nakase
Dean
-
Yasuhisa Sakata
Professor
Saga University
Kento Takenaka
Tokyo Medical and Dental University
Mitsuhiro Fujishiro
Professor
Nagoya University
Make your next move.
Prepare your application
Review drafts before you send them.